Document is current
Any future updates will be listed below
-
Authors
Hammad, Muhammed A. M. https://orcid.org/0000-0001-5396-1364
Miller, Jake A. https://orcid.org/0000-0002-2159-1909
Magill, Resa G.
Fattash, Akram Tayser
Yazar, Ramazan Omer
Abou Chawareb, Elia https://orcid.org/0000-0002-0757-896X
Sanford, Daniel
Amini, Eliad
Jenkins, Lawrence https://orcid.org/0000-0003-0125-673X
Barham, David W. https://orcid.org/0000-0001-6369-4423
Yafi, Faysal A. https://orcid.org/0009-0004-9408-482X
- License Information
-
More Information
Article History
Received: 8 July 2024
Revised: 18 March 2025
Accepted: 8 April 2025
First Online: 17 April 2025
Competing interests
: FAY: Coloplast: Advisory board, speaker; Endo: Advisory board; Haleon: Advisory board; Halozyme: Advisory board, speaker; Masimo: Intellectual property; Softwave: Advisory board; Sprout: Consultant; Vertica: Research investigator; Xialla: Advisory board. MAMH, JM, EAC, RGM, ATF, ROY, DS, EA, LJ, DWB: None.
: This study was reviewed and approved by the Institutional Review Board (IRB) at the University of California, Irvine (UCI IRB # 2220). Informed consent was obtained from all participants prior to their participation in the survey. All methods were carried out in accordance with relevant guidelines and regulations.
